Does amnesia specifically predict Alzheimer’s pathology? A neuropathological study

Bertoux, Maxime; Cassagnaud, Pascaline; Lebouvier, Thibaud; Lebert, Florence; Sarazin, Marie; Ber, Isabelle Le; Dubois, Bruno; Bank, NeuroCEB Brain; Auriacombe, Sophie; Hannequin, Didier; Wallon, David; Ceccaldi, Mathieu; Maurage, Claude‐Alain; Deramecourt, Vincent; Pasquier, Florence

doi:10.1016/j.neurobiolaging.2020.07.011

Cited by 20 publications

(14 citation statements)

References 53 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BCSB displayed good diagnostic accuracy, thus corroborating previous results 11,12,13,30 . DR was the best BCSB subtest, in comparing AD and controls.…”

Section: Discussionsupporting

confidence: 89%

Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study

Peles

Salvador

Souza

et al. 2022

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Background: Validation of cognitive instruments for detection of Alzheimer's disease (AD) based on correlation with diagnostic biomarkers allows more reliable identification of the disease. Objectives: To investigate the accuracy of the Brief Cognitive Screening Battery (BCSB) in the differential diagnosis between AD, non-AD cognitive impairment (both defined by cerebrospinal fluid [CSF] biomarkers) and healthy cognition, and to correlate CSF biomarker results with cognitive performance. Methods: Overall, 117 individuals were evaluated: 45 patients with mild cognitive impairment (MCI) or mild dementia within the AD continuum defined by the AT(N) classification [A+T+/-(N)+/]; 27 non-AD patients with MCI or mild dementia [A-T+/-(N)+/-]; and 45 cognitively healthy individuals without CSF biomarker results. All participants underwent evaluation using the BCSB. Results: The total BCSB and delayed recall (DR) scores of the BCSB memory test showed high diagnostic accuracy, as indicated by areas under the ROC curve (AUC): 0.89 and 0.87, respectively, for discrimination between AD and non-AD versus cognitively healthy controls. Similarly, total BCSB and DR displayed high accuracy (AUC-ROC curves of 0.89 and 0.91, respectively) for differentiation between AD and controls. BCSB tests displayed low accuracy for differentiation between AD and non-AD. The CSF levels of biomarkers correlated significantly, though weakly, with DR. Conclusions: Total BCSB and DR scores presented good accuracy for differentiation between patients with a biological AD diagnosis and cognitively healthy individuals, but low accuracy for differentiating AD from non-AD patients.

show abstract

“…The BCSB displayed good diagnostic accuracy, thus corroborating previous results 11,12,13,30 . DR was the best BCSB subtest, in comparing AD and controls.…”

Section: Discussionsupporting

confidence: 89%

Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study

Peles

Salvador

Souza

et al. 2022

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Memory loss, the cardinal symptom of AD, is also prevalent in other brain diseases, such as FTD, albeit with different underlying pathologies, while also a part of the normal aging process. Because of overlapping symptoms, memory impairment has proved to be unable to reliably distinguish AD from non-AD dementias [18,[20][21][22]50,51]. Recently, visuospatial dysfunction has emerged as a potential marker that can detect AD-even in its earliest stages.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, memory loss has been assumed to be the most sensitive and specific clinical marker of the underlying AD pathology. Recent studies, however, have raised questions as to memory loss' specificity to AD [17][18][19][20][21][22]. Bertoux et al [18], in particular, tested the memory of 91 volunteer patients who were in the early stages of cognitive decline.…”

Section: Visuospatial Dysfunction As a Biomarker For Admentioning

confidence: 99%

“…Recent studies, however, have raised questions as to memory loss' specificity to AD [17][18][19][20][21][22]. Bertoux et al [18], in particular, tested the memory of 91 volunteer patients who were in the early stages of cognitive decline. The researchers followed these patients until death after which autopsies were performed.…”

Section: Visuospatial Dysfunction As a Biomarker For Admentioning

confidence: 99%

See 1 more Smart Citation

Stereoscopic Depth Perception and Visuospatial Dysfunction in Alzheimer’s Disease

Kim

Lee

2021

Healthcare

View full text Add to dashboard Cite

With visuospatial dysfunction emerging as a potential marker that can detect Alzheimer’s disease (AD) even in its earliest stages and with disturbance in stereopsis suspected to be the prime contributor to visuospatial deficits in AD, we assessed stereoscopic abilities of patients with AD and mild cognitive impairment (MCI). Whereas previous research assessing patients’ stereoacuity has yielded mixed results, we assessed patients’ capacity to process coarse disparities that can convey adequate depth information about objects in the environment. We produced two virtual cubes at two different distances from the observer by manipulating disparity type (absolute vs. relative), disparity direction (crossed vs. uncrossed) and disparity magnitude, then had participants judge the object that appeared closer to them. Two patient groups performed as well as, or even better than elderly controls, suggesting that AD patients’ coarse disparity processing capacity is capable of supporting common tasks involving reaching, grasping, driving, and navigation. Results may help researchers narrow down the exact cause(s) of visuospatial deficits in AD and develop and validate measures to assess visuospatial dysfunction in clinical trials and disease diagnosis.

show abstract

“…58 Indeed, the classical concept of preservation of episodic memory in FTD 59 has been challenged by a series of cognitive, neuroimaging, and pathological investigations. [60][61][62] Here, none of the included studies indicated differences between PSP and bvFTD or PNFA in terms of episodic memory. However, individuals with PSP showed better verbal episodic memory scores than SD, which may be due to the specific and severe semantic deficit observed in SD patients.…”

Section: Discussionmentioning

confidence: 84%

Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review

Macedo

Mariano

Martins

et al. 2022

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Progressive supranuclear palsy (PSP) is the most common atypical parkinsonism and has executive dysfunction as a core feature. The magnitude of episodic memory disturbance in PSP is yet to be clarified. Objectives To investigate how impaired is episodic memory in PSP compared to healthy controls and other neuropsychiatric disorders. Also, we sought to identify the brain correlates underlying these memory disturbances. Methods We performed a systematic search on PubMed and Scopus, combining the terms “progressive supranuclear palsy” AND “memory”. The search was limited to papers published in English, French, Portuguese or Spanish, with no chronological filters. The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines were followed. Results The initial search returned 464 results. After extraction of duplicates, 356 records were screened, leading to inclusion of 38 studies. Most studies found that PSP patients had lower scores on episodic memory compared to healthy controls. In addition, the majority of studies suggest that PSP does not differ from Parkinson's disease and from atypical parkinsonism in terms of episodic memory performance. The same is seen for PSP and frontotemporal dementia. Conversely, episodic memory impairment seems to be greater in typical Alzheimer's disease compared to PSP. Neuroimaging findings indicate that striatofrontal structures may be involved in PSP episodic memory dysfunction, while no associations with mesial structures (including hippocampi) were found. Conclusions Episodic memory is impaired in PSP. Whether this amnesia refers to executive dysfunction is still controversial. More studies are warranted to clarify the neural basis of memory impairment in PSP.

show abstract

Does amnesia specifically predict Alzheimer’s pathology? A neuropathological study

Cited by 20 publications

References 53 publications

Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study

Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study

Stereoscopic Depth Perception and Visuospatial Dysfunction in Alzheimer’s Disease

Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review

Contact Info

Product

Resources

About